RxDoctor Payments Data

Maried Celkis, MD

Family Medicine · St Augustine, FLNPI 1194014365

Payments from drug & device makers

$1,677in general payments, 2019–2025

Across 84 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$517
  • Lilly USA, LLC$229
  • GSK$204
  • Otsuka America Pharmaceutical, Inc.$182
  • Pfizer$141
  • AbbVie$100
  • plus $304 from 10 others

What the payments were for

  • Food & beverage$1,677100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,677 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$138,281
Medicare patients
308
Services billed
2,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide145$167,321
MounjaroTirzepatide78$98,242
EliquisApixaban62$79,007
RexultiBrexpiprazole28$74,847
JardianceEmpagliflozin33$43,059
TrulicityDulaglutide32$39,967
WegovySemaglutide20$35,398
Repatha SureclickEvolocumab37$30,697
FarxigaDapagliflozin Propanediol30$26,524
MyrbetriqMirabegron16$10,697
Tresiba Flextouch U-100Insulin Degludec17$7,883
Breo ElliptaFluticasone/Vilanterol12$6,815
VyvanseLisdexamfetamine Dimesylate15$5,999
SynthroidLevothyroxine Sodium37$3,622
Atorvastatin Calcium328$3,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$517$202,719165 claims
Lilly USA, LLCMounjaro, Trulicity$229$138,210110 claims
PfizerEliquis, Paxlovid$141$80,43674 claims
Otsuka America Pharmaceutical, Inc.Rexulti$182$74,84728 claims
AstraZenecaFarxiga$94$26,52430 claims
Astellas Pharma US IncMyrbetriq$23$10,69716 claims
GSKBreo Ellipta$204$6,81512 claims
AbbVieSynthroid$100$3,62237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in St Augustine

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →